Phillip James Consulting’s Gilead Sciences GILD Stock Holding History

Phillip James Consulting’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.26K	Hold	10	–	–	﹤0.01%	251
2026 Q1	$1K	Buy	+10	New	+$1.4K	﹤0.01%	295

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Phillip James Consulting's GILD Position: Q2 2026 in Review

Phillip James Consulting held its Gilead Sciences (GILD) position steady in Q2 2026 at 10 shares worth $1.26K. The position accounts for ﹤0.01% of the portfolio, ranked #251.

Phillip James Consulting first reported a position in GILD in Q1 2026 and has held it in 2 quarters since. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Phillip James Consulting held 10 shares of Gilead Sciences worth $1.26K as of Q2 2026.
Phillip James Consulting left its Gilead Sciences share count unchanged in Q2 2026.
Gilead Sciences made up ﹤0.01% of Phillip James Consulting's portfolio in Q2 2026, its #251 holding.
Phillip James Consulting first reported a position in Gilead Sciences in Q1 2026 and has held it in 2 quarters since.
2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Phillip James Consulting's 13F filing for Q2 2026, filed 28 Jul 2026.